MediciNova, Inc.

NASDAQ:MNOV

Biotechnology

Healthcare
$1.33 -1.32%

-$0.02 today

Market cap
$68.14M
Beta
0.62
P/E (TTM)
-5.6
EPS (TTM)
-$0.24
52W Low $1.17High $1.96

Volume 0.12M

Average 0.04M

MNOV Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

MediciNova, Inc.NASDAQ: MNOV

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 49.22M shares rose 0.4% year over year, in line with the +0.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.4% holds above the trailing-twelve-month pace of +0.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
49.22M+0.3% QoQ
Last fiscal yearDec 2025
49.06M+0.0% YoY
LTMMar 2026
49.09M+0.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+0.0%——
3-year CAGR+0.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
49.06M USD
Year-over-year change
+0.0%
4-year CAGR
+0.2%

Weighted Avg Shares (Diluted) vs competitors

How MNOV compares with its peers on the latest reported figures

  • MNOV's LTM Mar 2026 weighted avg shares (diluted) of 49.09M shares is the 8th highest of the 11 companies compared; the peer median is 55.89M shares.
  • Its year-over-year change of +0.1% is the 10th highest of 11, against a peer median of +35.2%.
  • Over three fiscal years its annual growth of +0.0% compares with a peer median of +15.4%.
MNOV Competitors Peer median
Weighted Avg Shares (Diluted) for MNOV and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
VXRTVaxart, Inc.LTM Mar 2026232.46M +14.7%-22.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
FBIOFortress Biotech, Inc.LTM Mar 202695.09M +349.0%+261.1%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
MNOVMediciNova, Inc.LTM Mar 202649.09M +0.1%+0.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
XBITXBiotech Inc.LTM Mar 202630.49M +0.1%+0.1%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
Peer median (excluding MNOV) 55.89M+35.2%+15.4%

Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.04M01M0409.66K
Cost of Revenue0000378.61K
Gross Profit4.04M01M031.05K
Gross Margin100.0%—100.0%—7.6%
Research & Development8.1M9.14M5.66M7.2M7.15M
Selling, General & Admin5.72M5.48M5.24M5.48M6.16M
Operating Expenses14.25M14.63M10.9M12.68M13.31M
Depreciation & Amortization26.15K17.71K20.3K21.08K20.1K
EBITDA(10.11M)(14.05M)(8.55M)(11.02M)(11.97M)
EBITDA Margin-250.3%—-854.8%—-2922.4%
Operating Income(10.22M)(14.63M)(9.9M)(12.68M)(13.28M)
Operating Margin-253.0%—-990.0%—-3242.5%
Interest Income143.63K809.67K1.83M1.67M1.3M
Interest Expense00000
Other Income / Expenses84.13K562.39K1.33M1.63M1.29M
Income Before Tax(10.13M)(14.07M)(8.57M)(11.04M)(11.99M)
Pre-Tax Margin-250.9%—-856.8%—-2927.3%
Income Tax Expense2.57K2.82K3.05K5.54K5.99K
Net Income(10.13M)(14.07M)(8.57M)(11.05M)(12M)
Net Margin-251.0%—-857.2%—-2928.8%
EPS (Basic)(0.21)(0.29)(0.17)(0.23)(0.24)
EPS (Diluted)(0.21)(0.29)(0.17)(0.23)(0.24)
Weighted Avg Shares48.6M49.05M49.05M49.05M49.06M
Weighted Avg Shares (Diluted)48.6M49.05M49.05M49.05M49.06M

MediciNova, Inc.

NASDAQ:MNOV

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.